Nanoparticle pretreatment could boost solid tumor CAR T therapy
Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors.
The main hypothesis as to why CAR Ts have not shown efficacy in solid tumors is because they are overwhelmed by immunosuppressive factors in the tumor microenvironment (see BioCentury Innovations, May 3)...